(secondQuint)Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer.

 This trial is conducted in patients with the refractory metastatic colorectal cancer.

 Eligible patients are randomized into two arms at 1:1 ratio to receive Irinotecan-based regimen or Oxaliplatin-based regimen until progress of the disease, unacceptable toxicity or withdrawal of consent by the patient.

 Study evaluation time is until death of patient or a deadline set by the researchers.

.

 Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer@highlight

This is a prospective, open-lable, multicenter, randomized, controlled, phase II clinical study.

 The aim is to evaluate the efficacy of Irinotecan versus Oxaliplatin in the first-line treatment of refractory metastatic colorectal cancer.

